EUVIMEDEUVIMED entdecken
Crossref

Jatrorrhizine Alleviates Calcific Aortic Valve Disease via Interfering With Glycolysis Targeting ALDOA K42 Lactylation

Jiaqin Wu, Sixiang Wang, Pengfei Gao, Shunshun Wang, Huiming Yu, Qianqian Du, Minfu Liu, Shuwan Hou, Shan Jiang, Huajiao Xu, Siyi Ye, Fan Feng und 2 weitere

Phytotherapy Research · 2025-07 · 39 (7) · 3212-3224

DOI: 10.1002/ptr.8504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 08.06.2025. Verfasst von Jiaqin Wu und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Innovation and Attracting Talents "111" Base, Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bio…. Hauptthemen laut MEDLINE: Glycolysis, Aortic Valve, Berberine, Aortic Valve Stenosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calcific aortic valve disease (CAVD) is a common cardiovascular disorder. It is characterized by the thickening, fibrosis, and mineralization of aortic valve leaflets. These pathological changes can progress to heart failure if not managed effectively. Current surgical or transcatheter aortic valve replacement options exist, yet no pharmacotherapy has been established to impede CAVD advancement. Prior research by our team spotlighted the significance of lactate‐derived protein lactylation (Kla) in initiating valve calcification. In this study, we aim to uncover the anti‐calcification capacity of jatrorrhizine (JAT) and dissect its novel molecular underpinnings. The multi‐omics analyses were used to indicate that JAT affects the glycolysis of hVICs, thus exerting a therapeutic effect on CAVD. Then, molecular docking, immunoprecipitation, and site mutation were used to demonstrate that JAT can reduce the lactylation of ALDOA at the K42 site by binding to the lactyltransferases KAT5, thereby affecting its enzymatic stability and downstream metabolic pathways. JAT impeded CAVD by perturbing glycolysis and Kla. Notably, a decline in non‐histone Kla modification was linked to JAT inhibition of the osteogenic phenotype. ALDOA Kla, among glycolytic rate‐limiting enzymes, is a prime target of JAT anti‐calcification action. Crucially, the ALDOA K42la site was correlated with JAT‐induced suppression of Runx2 expression. JAT treatment effectively curbed osteogenic differentiation in human aortic valve interstitial cells (hVICs) and mitigated CAVD progression in mice. our findings pioneer the revelation that JAT mitigates calcification by targeting ALDOA K42la to interfere with glycolysis, suggesting its potential as a potent preventative agent against CAVD. JAT alleviates calcific aortic valve disease via interfering with glycolysis targeting ALDOA K42 lactylation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlycolysisAortic ValveBerberineAortic Valve StenosisCalcinosisAcyl Coenzyme AHumansAnimalsMiceMolecular Docking SimulationMaleMice, Inbred C57BLSaponinsTriterpenes

Stichwörter der Autor:innen

ALDOAcalcific aortic valve diseaseglycolysisjatrorrhizinelactylation

Substanzen

BerberinejatrorrhizineAcyl Coenzyme A18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesi…SaponinsTriterpenes

Autor:innen und Institutionen

  • National Innovation and Attracting Talents "111" Base, Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China.
  • School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
  • Ningbo Rehabilitation Hospital, Wenzhou Medical University, Ningbo, China.
  • School of Laboratory Medicine, Hubei University of Chinese Medicine, Wuhan, China.
  • Hubei Shizhen Laboratory, Wuhan, China.

ORCID-Profile: Kang Xu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, J., Wang, S., Gao, P., Wang, S., Yu, H., Du, Q., Liu, M., Hou, S., Jiang, S., Xu, H., Ye, S., Feng, F., Wang, C., & Xu, K. (2025). Jatrorrhizine Alleviates Calcific Aortic Valve Disease via Interfering With Glycolysis Targeting ALDOA K42 Lactylation. Phytotherapy Research, 39(7), 3212-3224. https://doi.org/10.1002/ptr.8504

Vancouver

Wu J, Wang S, Gao P, Wang S, Yu H, Du Q, et al. Jatrorrhizine Alleviates Calcific Aortic Valve Disease via Interfering With Glycolysis Targeting ALDOA K42 Lactylation. Phytotherapy Research. 2025;39(7):3212-3224. doi:10.1002/ptr.8504

BibTeX
@article{Wu2025,
  author = {Wu, Jiaqin and Wang, Sixiang and Gao, Pengfei and Wang, Shunshun and Yu, Huiming and Du, Qianqian and Liu, Minfu and Hou, Shuwan and Jiang, Shan and Xu, Huajiao and Ye, Siyi and Feng, Fan and Wang, Chunli and Xu, Kang},
  title = {Jatrorrhizine Alleviates Calcific Aortic Valve Disease via Interfering With Glycolysis Targeting ALDOA K42 Lactylation},
  journal = {Phytotherapy Research},
  year = {2025},
  volume = {39},
  number = {7},
  pages = {3212--3224},
  doi = {10.1002/ptr.8504}
}
Kostenlos starten →